Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy

Abstract

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the GI tract. Although a great deal of experience has been obtained with imatinib mesylate in patients with unresectable or metastatic GISTs, its role in the neoadjuvant setting is not well established. In this paper, we describe a case of successful resection of a giant recurrent GIST with imatinib mesylate as neoadjuvant therapy.

• Gastrointestinal stromal tumour
• imatinib mesylate
• neoadjuvant therapy